The market is growing due to increasing cancer research, rising demand for precision medicine, and expanding oncology drug development activities. Strong pharmaceutical R&D investments, advanced research infrastructure, and growing adoption of personalized treatment approaches are further driving market growth across the country.
Patient-derived xenograft/PDX models are advanced preclinical cancer research models created by implanting human tumor tissue into immunodeficient mice to study tumor behavior, drug response, and personalized cancer therapies. The U.S. patient-derived xenografts/PDX models market is growing due to increasing cancer prevalence, rising demand for precision medicine, and expanding oncology drug development activities. Pharmaceutical and biotechnology companies are increasingly adopting PDX model for accurate preclinical testing, biomarker discovery, and targeted therapy evaluation. Strong investments in translational research, advanced genomic technologies, and personalized treatment approaches are further accelerating market growth across the U.S. healthcare and life sciences sectors.
The global patient-derived xenografts/PDX models market size was estimated at USD 612.4 million in 2025 and is predicted to increase from USD 696.91 million in 2026 to approximately USD 2230.79 million by 2035, expanding at a CAGR of 13.8% from 2026 to 2035.
The U.S. patient-derived xenograft/PDX models market is expected to witness strong future growth due to increasing focus on precision oncology, targeted drug development, and personalized treatment approaches. Advancements in genomic profiling, AI-based research tools, and humanized mouse models are further expected to improve preclinical testing accuracy and accelerate innovation in cancer research.
| U.S. PDX Research Indicators | Numerical Data |
| Estimated New Cancer Cases | 2 Million |
| NIH Funding for Cancer Research | UDS 7 Billion |
| Success Rate of Drug Candidates in Clinical Trials | Below 10% |
The rising cancer burden and low clinical trials success rates are increasing the importance of patient-derived xenograft/PDX models in the U.S. These models provide more accurate tumor representation for preclinical drug testing and biomarker discovery. Growing oncology research funding and increasing focus on precision medicine are further supporting wider adoption of PDX platforms across pharmaceutical and biotechnology research.
The mouse-based PDX models segment held a dominant share of 82% in 2025 due to growing preference among pharmaceutical and biotechnology companies for greater control over experimental design, data security, and research timelines. These models enable faster iteration in oncology drug testing and improved reproducibility of results. Rising investments in internal R&D facilities and the need to protect proprietary cancer research data further strengthened the adoption of in-house PDX model development.
The gastrointestinal cancer segment led the U.S. patient-derived xenografts/PDX models market with a share of 24% in 2025 due to its high global and U.S. prevalence, including colorectal, gastric, and liver cancers. Increasing incidence linked to lifestyle factors, aging populations, and dietary habits is driving strong demand for advanced research models. PDX models are widely used to study tumor heterogeneity and drug response in GI cancers, supporting targeted therapy development and strengthening segment dominance in oncology research.
The drug discovery & development segment held a dominant share of 41% in 2025 due to increasing reliance on advanced preclinical models for identifying effective cancer therapies. PDX models are widely used to evaluate drug efficacy, toxicity, and tumor response in a more human-relevant system. Rising R&D investment, growing oncology pipelines, and the need to reduce late-stage clinical trial failures are further strengthening the dominance of this application segment.
The pharmaceutical & biotechnology companies segment dominated the U.S. patient-derived xenografts/PDX models market with a share of 46% in 2025 due to their strong focus on oncology drug discovery, precision medicine, and advanced preclinical testing. These companies extensively use PDX models to evaluate drug efficacy, study tumor biology, and reduce clinical trial failure. High R&D investments, expanding cancer drug pipelines, and growing adoption of translational research approaches further strengthened their dominant position in the market.
The model development segment led the U.S. patient-derived xenografts/PDX models market with a share of 31% in 2025 due to increasing demand for highly accurate and patient-relevant preclinical cancer models. Pharmaceutical and biotech companies rely on advanced PDX model development to ensure reliable tumor replication, better drug response prediction, and improved research outcomes. Rising oncology R&D activity, growing adoption of personalized medicine, and the need for customized tumor models further strengthened the dominance of model development services.
Leading companies in the U.S. patient-derived xenografts/PDX models market include Charles River Laboratories, The Jackson Laboratory, Crown Bioscience (U.S. operations), Altogen Labs, and Taconic Biosciences. These players are driving market growth through advanced tumor model development, expanded PDX libraries, and innovative preclinical oncology platforms. Continuous focus on precision medicine, strong investment in cancer research, and integration of translational and biomarker-driven studies further strengthen their leadership in the U.S. PDX models landscape.
By Model Type
By Tumor Type
By Application
By End User
By Host Type
By Implementation Type
By Service Type
